The Future of Biosimilars

Abstract

Biosimilars are to Biologic products what generic drugs are to chemical products, a more affordable solution to the increasing drug pricing without sacrificing the quality of the treatment.There is much debate in the health care industry as to whether Biosimilars will deliver on the same success achieved by the generic products, which can amount to up to 80% in some cases.   It is my view though that Biosimilars provide a viable path to cost reduction, quality improvement and affordable accessibility to medication.  In fact, the introduction of lower costs Biologics as intended by the Biosimilar market will force competition within the therapeutics treatment market that will both exertpricing pressure as well as inspire innovation in the entire ecosystem.